CRS Bio

About:

CRS Bio develops antibodies to treat chronic rhinosinusitis.

Description:

CRS Bio develops antibodies to treat chronic rhinosinusitis. The company was incorporated in 2016 and is based in San Francisco, California.

Total Funding Amount:

$8.4M

Headquarters Location:

San Francisco, California, United States

Founded Date:

2016-01-01

Founders:

Number of Employees:

1-10

Last Funding Date:

2016-10-03

IPO Status:

Private

Industries: